HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) All Versions of this Article: jcp.2007.052019v1 61/7/794    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Google Scholar Articles by Soor, G S Articles by Butany, J PubMed PubMed Citation Articles by Soor, G S Articles by Butany, J

Aortic stent grafts

¹ Department of Pathology, Toronto General Hospital/University Health Network, Toronto, Canada
² Department of Vascular Surgery, Toronto General Hospital/University Health Network, Toronto, Canada
³ Departments of Laboratory Medicine and Pathobiology, University of Toronto, Canada

Correspondence to:
Dr J Butany, Department of Pathology E4-301, Toronto General Hospital, Toronto, ON M5G 2C4, Canada; jagdish.butany{at}uhn.on.ca

Abdominal aortic aneurysms (AAAs) occur when weakened areas of the abdominal aortic wall result in a ballooning of the blood vessel. Attributed risk factors include smoking, atherosclerosis and hypertension. Traditionally, AAAs were treated with open surgery, involving a large abdominal incision and the placement of a synthetic graft. The introduction of endovascular aneurysm repair (EVAR) however, proved to have many advantages over open repair, chief among which is a lower perioperative morbidity and mortality rate. EVAR is likely to continue to evolve and the complications associated with this procedure will likely continue to decrease. In the meantime, the benefit of the continued, detailed analyses of explanted devices is twofold: (1) for future development of new devices; and (2) cognisance of complications that arise with any new device. This review is a guide to the many FDA approved stents which are commercially available, and those likely to become available following clinical trials.